Fig. 1From: Observational study on the tolerability of cluster subcutaneous immunotherapy in patients with rhinoconjunctivitis with or without asthma sensitized to pollen: the SIMO studyEvolution of the weekly frequency of ocular, nasal, and bronchial/asthma symptoms before immunotherapy and over each year of AIT treatment follow-up. *Frequency of symptoms: 0—Absence; 1—Infrequent 2 days/week; 2—Frequent 2–5 days/week; 3—Very frequent, more than 5 days/weekBack to article page